Mind control

Psygen Industries Ltd. and Larose Ventures Ltd. Announce Reverse Takeover Transaction of 1290442 B.C. Ltd. by Psygen Industries Ltd. and Brokered Financing Led by Eight Capital and Canaccord

Retrieved on: 
Wednesday, March 24, 2021
Counterculture of the 1960s, Entheogens, Lysergic acid diethylamide, Mind control, Clinical research, Health sciences, Microdosing, Drugs, Pharmacology

Psygen consists of a team of industry and business experts with over 25 years of direct experience manufacturing psychedelics.

Key Points: 
  • Psygen consists of a team of industry and business experts with over 25 years of direct experience manufacturing psychedelics.
  • The intention of this program is to obtain a market authorization for both a microdose LSD product and a macrodose LSD product.
  • Larose Ventures, SpinCo and Psygen will provide further details in respect of the Transaction in due course by way of press release.
  • Larose Ventures, SpinCo and Psygen assume no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

MindMed's LSD Neutralizer Study Begins

Retrieved on: 
Wednesday, February 17, 2021
Serotonin antagonists, Drugs, Receptor antagonists, Mind control, Counterculture of the 1960s, Entheogens, Lysergic acid diethylamide, Ketones, Psychedelic drug, 5-HT2A receptor, Ketanserin, Psychotherapy

BASEL, Switzerland, Feb. 17, 2021 /PRNewswire/ --MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced the start of a study for its LSD neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session.

Key Points: 
  • BASEL, Switzerland, Feb. 17, 2021 /PRNewswire/ --MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced the start of a study for its LSD neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session.
  • As shown in studies in healthy volunteers, administration of the 5-HT2A receptor antagonist ketanserin prior to the administration of LSD almost completely prevents the acute effects of LSD.
  • The study hypothesis is that ketanserin (40 mg), administered to healthy humans one hour after taking LSD, significantly shortens and reduces the acute subjective effects of the LSD (100 g) compared to LSD alone (100 g) followed by a placebo.
  • This study will support the patent application that was filed last year (preserving all worldwide rights) for a neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session.

'Psychedelics Market Update' by PsyIndex.com

Retrieved on: 
Tuesday, December 15, 2020
Counterculture of the 1960s, Entheogens, Lysergic acid diethylamide, Mind control, Psychedelic drug, Drugs, Branches of biology, Psychoactive drugs

The PsyIndex rallied nearly 36% to $188.61 last week in a broad sector-wide rally.

Key Points: 
  • The acquisition provides a range of psychedelic derivative drug candidates with clinical studies anticipated to begin next year.
  • MindMed rose 75% last week and announced a successful pre-IND meeting with the FDA for Project Lucy.
  • The new IND program will commence in August 2021 with a Phase 2b clinical trial for LSD-assisted therapy in anxiety.
  • CFN connects investors with new market opportunities while helping consumers find innovative products that enhance their lives.

BetterLife’s Recent Acquisition: Taking LSD from Experimental to a Major Therapeutic Application

Retrieved on: 
Tuesday, December 15, 2020
Drugs, Counterculture of the 1960s, Entheogens, Lysergic acid diethylamide, Mind control, 2-Bromo-LSD, Psychedelic drug, Branches of biology, Neurochemistry

With the acquisition of this intellectual property, we have solved the problem that has plagued psychedelic therapies for so many decades.

Key Points: 
  • With the acquisition of this intellectual property, we have solved the problem that has plagued psychedelic therapies for so many decades.
  • I'm very excited by the opportunities presented by BetterLife's experienced clinical research team enabling Transcend's novel therapeutics to reach human beings in need of help.
  • 2-Bromo-LSD is a nontoxic second-generation LSD-derived molecule that mimics the therapeutic potential of LSD, without the psychedelic effects or hallucinations.
  • BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies.

Neural Implants Market Size to Reach Revenues of USD 7.2 Billion by 2025 - Arizton

Retrieved on: 
Thursday, October 29, 2020
Branches of biology, Human–computer interaction, Biomedical engineering, Prosthetics, Neuroprosthetics, Brain implant, Mind control, Multimodal interaction, Implant

The global neural implants or brain implants market is expected to grow at a CAGR of approximately 11% during the period 20192025.

Key Points: 
  • The global neural implants or brain implants market is expected to grow at a CAGR of approximately 11% during the period 20192025.
  • Key Highlights Offered in the Report:
    The global neural implants market is anticipated to reach more than $7 billion by 2025 with a strong double-digit growth of around 11% over the forecast period.
  • Increasing uptake of minimally invasive pain relief treatment is one of the key factors driving the growth of the global neural implants market.
  • Emergence of closed-loop neural implants is anticipated to drive the growth of the global neural implants market.

Outlook on the Brain Implants Global Market to 2025 - Increased Incidences of Neurological Disorders is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, August 14, 2020
Health, Medical devices, Other Health, Medicine, Branches of biology, Clinical medicine, Prosthetics, Brain implant, Brain–computer interfacing, Mind control, Multimodal interaction, Implant, Parkinson's disease, Epilepsy in animals

The primary factors that drive the growth of the market include increased incidences of neurological disorders such as Epilepsy and Parkinson's diseases.

Key Points: 
  • The primary factors that drive the growth of the market include increased incidences of neurological disorders such as Epilepsy and Parkinson's diseases.
  • Thus, such incidences are likely to propel the brain implants market growth during the forecast period.
  • Asia-Pacific is estimated to exhibit a significant growth rate in the global brain implants market during the forecast period.
  • Moreover, the study of the global brain implants market report covers the analysis of various players operating in the market.

Psychedelic Pharmaceutical Company MindMed Develops LSD Neutralizer Technology To Shorten and Stop LSD Trips

Retrieved on: 
Wednesday, April 22, 2020
Psychoactive drugs, Drugs, Receptor agonists, Entheogens, RTT, Counterculture of the 1960s, Lysergic acid diethylamide, Mind control, Psychedelic therapy, Medication, Pharmaceutical industry, Psychedelic drug

MindMed is the leading psychedelic pharmaceutical company and the Liechti Laboratory is the leading research center focused on the pharmacology of psychedelic substances.

Key Points: 
  • MindMed is the leading psychedelic pharmaceutical company and the Liechti Laboratory is the leading research center focused on the pharmacology of psychedelic substances.
  • This advancement paves the way for greater therapeutic applications of LSD and shorter-acting psychedelic therapy treatments.
  • MindMed gained exclusive, worldwide rights to technology covered by the recently filed patent application based on inventions previously generated by the Liechti Laboratory in LSD and any future LSD research funded by MindMed.
  • Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering.

Psychedelic Pharmaceutical Company MindMed Develops LSD Neutralizer Technology To Shorten and Stop LSD Trips

Retrieved on: 
Tuesday, April 21, 2020
Psychoactive drugs, Drugs, Receptor agonists, Entheogens, RTT, Counterculture of the 1960s, Lysergic acid diethylamide, Mind control, Psychedelic therapy, Medication, Pharmaceutical industry, Psychedelic drug

MindMed is the leading psychedelic pharmaceutical company and the Liechti Laboratory is the leading research center focused on the pharmacology of psychedelic substances.

Key Points: 
  • MindMed is the leading psychedelic pharmaceutical company and the Liechti Laboratory is the leading research center focused on the pharmacology of psychedelic substances.
  • This advancement paves the way for greater therapeutic applications of LSD and shorter-acting psychedelic therapy treatments.
  • MindMed gained exclusive, worldwide rights to technology covered by the recently filed patent application based on inventions previously generated by the Liechti Laboratory in LSD and any future LSD research funded by MindMed.
  • Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering.

Insights into the Worldwide Cranial Implants Industry to 2024 - An Increase in Target Population is Anticipated to Boost the Growth of the Market - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 16, 2020
Biotechnology, Health, Surgery, Medical devices, Human–computer interaction, Neuroscience, Emerging technologies, Brain implant, Brain–computer interfacing, Mind control, Multimodal interaction, Neuroprosthetics, Cranial, Medical Subject Headings, Skull

The cranial implants market is poised to grow by $ 245.22 mn during 2020-2024 progressing at a CAGR of 6% during the forecast period.

Key Points: 
  • The cranial implants market is poised to grow by $ 245.22 mn during 2020-2024 progressing at a CAGR of 6% during the forecast period.
  • The report on the cranial implants market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • In addition, increase in target population is anticipated to boost the growth of the market as well.
  • This study identifies the growing demand for 3d printing/modeling skull as one of the prime reasons driving the cranial implants market growth during the next few years.

The Global Cranial Implants Market size is expected to reach $1.4 billion by 2025, rising at a market growth of 6.2% CAGR during the forecast period

Retrieved on: 
Monday, January 13, 2020
Human–computer interaction, Biomedical engineering, Neuroprosthetics, Neuroscience, Prosthetics, Brain implant, Mind control, Multimodal interaction

The Global Cranial Implants Market size is expected to reach $1.4 billion by 2025, rising at a market growth of 6.2% CAGR during the forecast period.

Key Points: 
  • The Global Cranial Implants Market size is expected to reach $1.4 billion by 2025, rising at a market growth of 6.2% CAGR during the forecast period.
  • One of the main factors pushing the worldwide cranial implant market is the increase in the target population that requires cranial implants.
  • Developing patient-specific and technically advanced products with value-added functions are key competitors operating the global cranial implants market.
  • During the forecast period, the polymer material is expected to hold the largest market share of cranial implants.